Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Foghorn Therapeutics Inc. - Common Stock (NQ: FHTX )

4.800 +0.210 (+4.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 256,290
Open 4.650
Bid (Size) 1.920 (2)
Ask (Size) 5.000 (1)
Prev. Close 4.590
Today's Range 4.550 - 4.860
52wk Range 2.700 - 10.25
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. 
Via Benzinga

Performance

YTD
+4.58%
+4.58%
1 Month
-26.94%
-26.94%
3 Month
-38.30%
-38.30%
6 Month
-4.00%
-4.00%
1 Year
-20.00%
-20.00%

More News

Read More
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics: Q4 Earnings Insights
Via Benzinga
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in the BMO Oncology Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.